Brown Gibbons Lang & Company’s Post

Great Healthcare PE event organised by McDermott Will & Emery Key takeways: 1. Deal activity stabilising with $129bn of healthcare deals in H1 2024. Still below pre-pandemic levels 2. Deal mix has shifted from buyout to strategics, driving most of deal activity in past 18 months 3. Dry powder at record high, pressure from LPs. “DPI is the new IRR” 4. Pharma services opportunities still relevant for PE. Buy and build strategy needs strong integration efforts. 5. Medtech, Consumer health/OTC carve outs on the rise. 6. Geopolitical “black swans” hard to predict - but fundamentally strong assets will ride the cycles. 7. With many Pharma facing patent cliffs by 2030, Biotech acquisitions will be strong in next 2-3 years. 8. Majority believe 2025 will be a strong year for PE in healthcare. Medi-Tech Insights #privateequity #healthcare #biotech #consumerhealth #otc #medtech #pharma #mergersandacquisitions

Looking forward, PE sponsors must instill higher confidence in identifying value-creation opportunities at an earlier stage. This is the most straightforward way to justify larger capital commitments. Moreover, sponsors ought to broaden their perspective beyond due diligence, focusing on a more holistic range of operational, technological, and governmental factors. We need strategic fund strategies, paired with ethical and meaningful practices. #PrivateEquity #Healthcare #Strategy #ValueCreation

How can pharma companies regain shareholders' trust? Embracing the recent upswing in M&A is one way to do it, but only if it's done the right way, according to industry watchers like PwC's Greg Rotz and Allen & Overy's Nicole Daley. Read more at PharmaVoice.

📊 What is the life sciences investment outlook for 2024? 🧬 Understanding the deal landscape by sector is a continuing focus for KPMG US and the ever-evolving landscape in #HealthcareandLifeSciences always has my attention. I’m looking forward to this webcast where Alasdair Milton, PhD, Martin Mazin and Victor Gatti will take a deep dive into the 2024 life sciences investment outlook and provide actionable strategies to navigate the #opportunities and challenges that lie ahead for emerging #biopharma companies. This one will be worth your time. https://lnkd.in/gx5N3eWi #KPMGHCLS #HCLS #KPMGDealAdvisory #DealAdvisory #KPMGStrategy #performanceimprovement #mergersandaquisitions #alternativedealstructures

KPMG's 2024 Healthcare & Life Sciences Investment Outlook identifies key trends driving growth in the industry. From operational efficiency to strategic acquisitions, learn where leaders are focusing their capital.   Discover our comprehensive analysis below 👇 and click to learn more: https://lnkd.in/eaMEYRcF   #HealthcareInvestment #KPMGInsights #MergersAndAcquisitions

🧬 European Life Sciences deals overview for 2023 & 2024 outlook 📈 https://lnkd.in/dsiQ5NpB Excited to share our latest publication. In this report, we delve into the dynamic landscape of life sciences investments across European targets, highlighting key trends across each deal type, notable deals, and emerging opportunities shaping the industry Explore the full report to stay informed and gain strategic perspectives on the future of life sciences investments in Europe #LifeSciences #Biotech #Investments

We continue to see lots of opportunities in life sciences investing. While 2023 deal activity was down vs 2021 and 2022, the multi-year trend continues to be up and to the right. Find out more in our 2024 Global Healthcare Private Equity Report.

Ready to go public in the life sciences field? The process of getting from Point A to Point B in your IPO can be complex, with input from many different departments and stakeholders. Add on the extra regulations applying to life sciences companies, and it's clear: You need to approach this process in a careful, well-informed way. Fortunately, the CFGI team has created a step-by-step guide to taking your life sciences firm public: https://bit.ly/4bC199Q #CFGI #LifeSciences #IPO #GoingPublic

Exciting Trends in Life Sciences Private Equity The life sciences sector has been a key focus for private equity (PE) funds seeking innovative and recession-resistant opportunities. The latest insights from Bain's 2024 Global Healthcare Private Equity Report reveal intriguing dynamics in the industry. - Deal Value Dilemma: Despite consistent interest, private equity deal value in 2023 faced challenges in matching the heights of 2022, partly attributed to a biotech funding slowdown. However, a silver lining emerged as investors increasingly favored early-stage therapies and precommercial medical devices. - Global Forces at Play: The ripple effects of the Inflation Reduction Act (IRA) and the surge in investments in cell, gene, and RNA therapies are reshaping the landscape for service providers. Strategic considerations around drug negotiation provisions and evolving modalities are becoming pivotal for successful investments. - AI's Transformative Role: The article highlights the transformative impact of artificial intelligence (AI) in accelerating product development and commercialization within the life sciences sector. - Investor Implications: Investors are advised to navigate these trends with a blend of operational and commercial excellence, alongside scientific proficiency. The potential for lucrative returns exists, especially for those who can seize opportunities in the evolving landscape of advanced modalities and strategic outsourcing. Explore the Full Report: For a comprehensive dive into the trends shaping life sciences private equity, explore Bain's 2024 Global Healthcare Private Equity Report. #LifeSciences #PrivateEquity #HealthcareInnovation #InvestmentTrends #BainReport2024

Thanks to Ryan Dolan and Kelly Provost from CFGI for hosting a fun Life Sciences event last night at the ICA in Boston. Some key takeaways from an informative panel: 1) The life sciences IPO market has been relatively weak the past few years, with only 10 or so IPOs / year. Historically, in an "average" year, there are 30 - 40 life sciences IPOs. 2) The 3 life sciences IPOs that will price this week are a positive sign / trend. 3) Per Susanne Mulligan, 2025 should be a "good" year for life sciences IPOs. This will be driven by combination of factors, including: a) likely 25bp interest rate cut b) getting past the presidential election (the market does not like uncertainty) c) possible change in leadership at FTC (which should result in return of big M&A deals in life sciences) d) large back-log of well-funded, high-quality life sciences companies that are in the IPO queue (per Bruce Booth, roughly 150 private companies have raised cross-over rounds in the past few years, and many (1/3?) of these are currently on file confidentially with the SEC) 4) If Susanne is right, then Ryan's golf game is going to take a major hit in 2025. (Sorry Ryan!)